New Risk Stratification for Adjuvant Nivolumab for High‐risk Muscle‐invasive Urothelial Carcinoma
BJUI COMPASS（2024）
Key words
adjuvant therapy,immune-related adverse events,neoadjuvant therapy,nivolumab,urinary bladder neoplasms
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined